CYTOKINETICS INC Q1 FY2025 earnings call

Robert Blum discussed the extension of the PDUFA date for aficamten's NDA to December 2025 due to a major amendment for REMS submission, and interactions with FDA on safety monitoring. Andrew Callos talked about commercial readiness like Salesforce recruiting, sales operational planning, patient support program, and European commercial activities. Fady Malik provided updates on clinical trials: MAPLE-HCM results expected this month, ACACIA-HCM completing enrollment ahead of schedule and changes to its primary endpoint. Stuart Kupfer gave updates on CK-586's AMBER-HFpEF trial and omecamtiv mecarbil's COMET-HF trial. Isaac Ciechanover mentioned a Series B financing of Imbria Pharmaceuticals. Sung Lee provided financial results and maintained full-year 2025 financial guidance. Robert Blum outlined upcoming milestones including MAPLE-HCM results, ACACIA-HCM top-line results, and enrollment in various trials.

No specific product segment financial performance with absolute terms and revenue contribution % provided in the transcript.

Maintained full-year 2025 GAAP operating expense guidance between $670 million and $710 million. Stock-based compensation is expected to be between $110 million and $120 million. The range incorporates the U.S. PDUFA date extension for aficamten driving a decrease in G&A expense and the acceleration of ACACIA-HCM increasing R&D expense.

Uncertainties in FDA review process affecting PDUFA date; potential market dynamics and regulatory approvals impacting commercialization of aficamten.

Q: Based on the failure of ODYSSEY and BMS verbiage around obstructive HCM being different from nonobstructive, getting questions on what that means for ACACIA.

A: Robert Blum spoke generally and Fady Malik answered specific questions about ACACIA's design and optimism.

Q: Did the FDA initially guide to not submit REMS? What happened?

A: Robert Blum explained the interactions with FDA, stating they made a determination based on feedback and submitted REMS when FDA requested.

Q: Can you comment on whether the REMS submitted to FDA is consistent with investor communications?

A: Robert Blum and Fady Malik discussed consistency of REMS with previous communications.

Q: What's left for aficamten to be differentiated after Camzyos label changes?

A: Robert Blum stated there remains opportunity for differentiation based on submitted REMS.

Q: Did FDA indicate no REMS needed during meetings? Why no disclosure back when submitting NDA?

A: Robert Blum answered about FDA interactions and reasons for not disclosing earlier.

Q: Confidence in differentiated REMS being ETASU?

A: Robert Blum stated assumption of ETASU REMS approach.

Q: Thinking about submitting MAPLE after the fact for EMEA and China?

A: Fady Malik said adding MAPLE to ongoing reviews would be disruptive.

Q: Confidence in newly submitted REMS being accepted?

A: Robert Blum said there's back and forth but believed in process.

Q: Thoughts on nHCM uptake and EU vs U.S. dynamics?

A: Andrew Callos discussed nHCM uptake and market development.

Q: Characterize MAPLE-HCM market opportunity?

A: Robert Blum and Andrew Callos talked about MAPLE's potential incremental impact.

Q: Confidence in REMS acceptance and late cycle meeting?

A: Robert Blum discussed REMS acceptance and expectation of late cycle meeting in June.

Q: REMS submission and FDA mid-cycle review?

A: Robert Blum provided color on mid-cycle review and REMS submission.

Q: Why not include REMS initially?

A: Robert Blum explained calculated decision based on FDA feedback.

Q: Real-world studies on SEQUOIA data and septal reduction surgery?

A: Fady Malik discussed real-world data and septal reduction implications.

Q: CK-586 AMBER study data disclosure and effective doses?

A: Stuart Kupfer talked about data disclosure and dose-finding approach in CK-586 study.

Q: Regulators' alignment on ACACIA endpoints?

A: Fady Malik discussed regulators' alignment on ACACIA endpoints.

Q: REMS as procedural mishap?

A: Robert Blum denied mishap and explained REMS process.

Q: Edgewise clinical data and ejection fraction measurements?

A: Fady Malik commented on Edgewise data and ejection fraction measurement differences.